Si-Tien Wang

Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review

Study Type – Symptom prevalence (case series)
Level of Evidence 4

Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.

BACKGROUND: Patients with myelodysplastic syndrome (MDS) or severe anemia requiring repeated red blood cell (RBC) transfusions risk developing transfusional iron overload, which can reduce survival. Iron chelation therapy (ICT) has been shown to improve survival and quality of life in patients; however, ICT utilization in clinical practices is not well understood.

Lifetime costs to Medicare of providing care to patients with chronic lymphocytic leukemia

Abstract This study estimated the average lifetime costs of patients with chronic lymphocytic leukemia (CLL) relative to similar patients without cancer. An analysis of the Medicare 5% database (1999–2007) was conducted. Each patient with CLL was matched up to three patients without cancer based on year of birth, gender, race and state. Average total lifetime costs were estimated using the Kaplan–Meier sample average estimator and stratified by treatments. For patients who died, average monthly costs during continuing and terminal phases were compared between cohorts. A total of 7463 patients with CLL and 22 331 matched controls were identified (mean age: 76 years; proportion of women: 49%). The mean observation period was 39.4 months for patients with CLL and 45.9 months for matched controls. Patients with CLL incurred average costs of

Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics

87 151 compared to

Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -;Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

47 642 for matched controls (p < 0.001). Among common CLL treatments, average costs per patient were

The Cost-Effectiveness of Bortezomib Plus Melphalan and Prednisone Versus Lenalidomide Plus Melphalan and Prednisone with Continuous Lenalidomide Maintenance Treatment for the Initial Treatment of Multiple Myeloma In the United States

5140 for rituximab and

The Cost-Effectiveness of Bortezomib for the Initial Treatment of Multiple Myeloma in the United States.

953 for radiation therapy. Compared to matched controls, patients with CLL had significantly higher monthly costs during the continuing and terminal phases. This study showed that average lifetime costs to Medicare were

PSY19 THE COST-EFFECTIVENESS OF BORTEZOMIB PLUS MELPHALAN AND PREDNISONE VERSUS LENALIDOMIDE PLUS MELPHALAN AND PREDNISONE WITH CONTINUOUS LENALIDOMIDE MAINTENANCE TREATMENT FOR THE INITIAL TREATMENT OF MULTIPLE MYELOMA IN THE UNITED STATES

87 151 for patients with CLL compared to

Monitoring and Treatment of Transfusional Iron Overload: Findings from an Electronic Medical Records Review Study at the Moffitt Cancer Center and Research Institute.

47 642 for matched controls without cancer, for a significant difference of

PSY12 TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN PATIENTS WITH MYELODYSPLASTIC SYNDROME OR SEVERE ANEMIA: DATA FROM MULTI-CENTER CLINICAL PRACTICES

39 509.